MedTrace Logo

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

NCT01662336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2018-01-29

Study results available
· View outcomes & findings →

Summary

The overall purpose of the study was to describe the real-life adherence, effectiveness and safety of the Kaletra Adherence Support Assistance (KASA) Program in human immunodeficiency virus (HIV)-positive patients who were receiving treatment with lopinavir / ritonavir (LPV/r; Kaletra®) in Canada.

Conditions

  • Human Immunodeficiency Virus Infection

Interventions

DRUG

Lopinavir / ritonavir

Prescribed according to the product monograph and physician's discretion.

BEHAVIORAL

Kaletra Adherence Support Assistance Program

A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Christina Pelizon, MD · AbbVie Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01662336 on ClinicalTrials.gov